Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy.
Aggressiveness index
HCV related HCC
Hepatocellular carcinoma
Tumor pattern
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
10
2019
accepted:
04
05
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Hepatitis C virus (HCV) represents a major risk factor for hepatocellular carcinoma (HCC) development and anti-HCV therapy is a significant measure to reduce the incidence of HCC, however development of HCC in HCV treated patients is an emerging clinical problem which needs to be investigated. In this study we aim to analyze association between anti-HCV therapy and tumor pattern of HCV related HCC patients. Hepatocellular Carcinoma (HCC) patients with seropositivity for hepatitis C virus (HCV) antibodies, registered at three tertiary care hospitals of Rawalpindi and Islamabad, Pakistan during August 2017 to July 2018 were enrolled. Selected patients were then segregated in two groups on the basis of their HCV treatment history i.e., "TN" (HCV Treatment Naïve i.e. having no history/medical record for treatment prior to HCC diagnosis) and "TH" (Treated for HCV infection). Aggressiveness index (AgI) scoring system was applied to determine the tumor pattern. Univariate and multivariate analysis was carried out to analyze the independent effect of anti-HCV therapy on tumor pattern. Out of 234 consecutive HCC patients, 171 HCV-related HCC patients were enrolled in final analysis and labeled as "TN" ( We observed raised neutrophil to lymphocyte ratio and prominence of younger age with aggressive tumor biology in HCV treated HCC patients. These observations highlight the need for a longitudinal prospective study on HCV positive subjects treated with antivirals, irrespective of treatment response.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) represents a major risk factor for hepatocellular carcinoma (HCC) development and anti-HCV therapy is a significant measure to reduce the incidence of HCC, however development of HCC in HCV treated patients is an emerging clinical problem which needs to be investigated. In this study we aim to analyze association between anti-HCV therapy and tumor pattern of HCV related HCC patients.
METHODS
METHODS
Hepatocellular Carcinoma (HCC) patients with seropositivity for hepatitis C virus (HCV) antibodies, registered at three tertiary care hospitals of Rawalpindi and Islamabad, Pakistan during August 2017 to July 2018 were enrolled. Selected patients were then segregated in two groups on the basis of their HCV treatment history i.e., "TN" (HCV Treatment Naïve i.e. having no history/medical record for treatment prior to HCC diagnosis) and "TH" (Treated for HCV infection). Aggressiveness index (AgI) scoring system was applied to determine the tumor pattern. Univariate and multivariate analysis was carried out to analyze the independent effect of anti-HCV therapy on tumor pattern.
RESULTS
RESULTS
Out of 234 consecutive HCC patients, 171 HCV-related HCC patients were enrolled in final analysis and labeled as "TN" (
CONCLUSION
CONCLUSIONS
We observed raised neutrophil to lymphocyte ratio and prominence of younger age with aggressive tumor biology in HCV treated HCC patients. These observations highlight the need for a longitudinal prospective study on HCV positive subjects treated with antivirals, irrespective of treatment response.
Identifiants
pubmed: 32508980
doi: 10.1186/s13027-020-00300-z
pii: 300
pmc: PMC7251734
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
BMJ. 2010 May 04;340:c2420
pubmed: 20442238
J Viral Hepat. 2010 Nov;17(11):749-56
pubmed: 20723036
N Engl J Med. 1989 Nov 30;321(22):1501-6
pubmed: 2509916
Hepatology. 2004 Dec;40(6):1426-33
pubmed: 15565616
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Hepatol. 2012 Nov;57(5):1013-20
pubmed: 22732513
Gastroenterology. 2015 Jul;149(1):190-200.e2
pubmed: 25754160
Hepatology. 2012 Mar;55(3):759-68
pubmed: 21858849
J Hepatol. 2017 Mar;66(3):485-493
pubmed: 27780714
Open Virol J. 2018 Feb 28;12:26-32
pubmed: 29541276
Sci Rep. 2017 Mar 31;7:45846
pubmed: 28361988
Adv Immunol. 2006;90:1-50
pubmed: 16730260
Liver Int. 2017 Oct;37(10):1526-1534
pubmed: 28418617
World J Gastroenterol. 2018 Apr 21;24(15):1641-1649
pubmed: 29686471
Hepatology. 2015 Oct;62(4):1190-200
pubmed: 26146815
Epidemiol Infect. 2018 Oct;146(13):1612-1618
pubmed: 29991359
Clin Gastroenterol Hepatol. 2017 Feb;15(2):273-281.e1
pubmed: 27521507
J Hepatol. 2006 Apr;44(4):723-31
pubmed: 16488051
J Gastroenterol Hepatol. 2005 May;20(5):752-8
pubmed: 15853990
World J Gastroenterol. 2018 Jun 28;24(24):2582-2595
pubmed: 29962815
Hepatology. 2009 May;49(5 Suppl):S56-60
pubmed: 19399807
World J Gastroenterol. 2017 Oct 7;23(37):6802-6816
pubmed: 29085224
Cancer Causes Control. 2010 Dec;21(12):1967-77
pubmed: 21069448
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Open Virol J. 2018 Feb 28;12:16-25
pubmed: 29541275
J Viral Hepat. 2012 Jul;19(7):449-64
pubmed: 22676357
Hepatol Int. 2018 Nov;12(6):523-530
pubmed: 30242733
Cancer. 2004 Oct 1;101(7):1616-22
pubmed: 15378504
Hepatology. 2007 Mar;45(3):579-87
pubmed: 17326216
J Hepatol. 2016 Oct;65(4):727-733
pubmed: 27349488
Asian Pac J Cancer Prev. 2014;15(18):7563-7
pubmed: 25292029
J Vasc Interv Radiol. 2011 Jul;22(7):917-23
pubmed: 21571545
Liver Cancer. 2016 Jul;5(3):190-7
pubmed: 27493894
Hepatology. 2002 Nov;36(5 Suppl 1):S74-83
pubmed: 12407579
BMC Cancer. 2013 Feb 02;13:52
pubmed: 23374755
BMC Cancer. 2014 Feb 21;14:117
pubmed: 24559042
J Hepatol. 2003 Dec;39(6):1076-84
pubmed: 14642630
J Clin Lab Anal. 2019 Jun;33(5):e22876
pubmed: 30843304
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Hepatol. 2016 Jun;64(6):1217-23
pubmed: 27059129
J Viral Hepat. 2018 Jun;25(6):623-630
pubmed: 29274197
Oncology. 2016;90(4):215-20
pubmed: 26974336
J Clin Virol. 2011 Dec;52(4):321-7
pubmed: 21924672
Hepatology. 2018 Sep;68(3):1010-1024
pubmed: 29604220
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
J Integr Oncol. 2016 Oct;5(4):
pubmed: 28580457
J Hepatol. 2019 May;70(5):874-884
pubmed: 30684506
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):75-79
pubmed: 30199473
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592
World J Gastroenterol. 2009 Oct 28;15(40):5080-5
pubmed: 19860002
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hepatology. 2007 Nov;46(5):1350-6
pubmed: 17680653
World J Hepatol. 2012 Dec 27;4(12):342-55
pubmed: 23355912
Semin Oncol. 2014 Apr;41(2):252-8
pubmed: 24787296
Gut. 2016 Apr;65(4):693-701
pubmed: 25670811
Cancer. 1985 Aug 15;56(4):918-28
pubmed: 2990661
J Gastroenterol. 2003;38(2):153-7
pubmed: 12640529
J Gastroenterol Hepatol. 2016 May;31(5):1009-15
pubmed: 26584407
N Engl J Med. 2011 Jun 23;364(25):2429-38
pubmed: 21696309
Virology. 2008 Jan 20;370(2):237-45
pubmed: 18006035
PLoS One. 2019 Feb 20;14(2):e0212033
pubmed: 30785909
Gastroenterol Res Pract. 2016;2016:5942306
pubmed: 26955390
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568